8 January 2026
VBB advises Adjuvant Global Health Technologies on investment in Phoenix Biosciences
1 min read
VBB has advised private investment fund Adjuvant Global Health Technologies (Adjuvant) on its investment in Phoenix Biosciences.
In the context of the Belgian pre-pack bankruptcy procedure relating to the distressed Univercells group, new corporate vehicle Phoenix Biosciences has acquired certain assets of Univercells subsidiary Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics.
Adjuvant was a shareholder in the Univercells group and, alongside fellow shareholders, has contributed to a capital raise for Phoenix Biosciences.
The VBB team comprised partner Caroline DAOUT, counsel Virginie Lescot and associate Jens Westerwoudt.
News & insights
10 min
read
read
Briefings
Dual-Use Items: AG Backs Broad Test in Case C-538/25
13 October 2026
1 min
read
read
Briefings
EU General Court Ruling on Customs Classification of Split Consignments in EU Assembly Operations
9 October 2026
2 min
read
read
Briefings
Poland – Polish Competition Authority Fines Medicine Wholesalers for Illegally Exchanging Confidential Information
23 September 2026
2 min
read
read
Briefings
Belgian Competition Authority Imposes fine of EUR 29.8 Million on Pharmaceutical Wholesaler Pharma Belgium-Belmedis
18 February 2022
2 min
read
read
Briefings
Belgium Publishes Third Annual Report Regarding Screening of Foreign Direct Investment
11 September 2026
10 min
read
read
Briefings
Public procurement rules being set aside in European defence deals
21 September 2026
4 min
read
read
Briefings
Belgian Competition Authority Closes Live Nation / Pukkelpop Investigation on Commitments
21 September 2026
5 min
read
read
Briefings
Urban Wastewater Treatment Directive Remains Focus of Litigation and Parliamentary Activity
15 September 2026
